Zacks Investment Research upgraded shares of Dermira (NASDAQ:DERM) from a sell rating to a hold rating in a report issued on Tuesday.

According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “

Several other equities analysts have also issued reports on the company. BidaskClub lowered Dermira from a buy rating to a hold rating in a research report on Tuesday. Guggenheim reaffirmed a buy rating and issued a $30.00 price target on shares of Dermira in a research report on Thursday, December 14th. Mizuho lowered their price target on Dermira from $43.00 to $39.00 and set a buy rating for the company in a research report on Tuesday, December 12th. Cantor Fitzgerald set a $45.00 price target on Dermira and gave the stock a buy rating in a research report on Wednesday, November 29th. Finally, Leerink Swann reaffirmed an outperform rating and issued a $41.00 price target (down previously from $47.00) on shares of Dermira in a research report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. Dermira presently has a consensus rating of Hold and an average target price of $41.00.

Dermira (DERM) traded up $0.74 on Tuesday, hitting $27.44. The stock had a trading volume of 1,063,459 shares, compared to its average volume of 505,085. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40. The stock has a market cap of $1,112.70, a price-to-earnings ratio of -4.40 and a beta of 0.80. Dermira has a 12-month low of $21.35 and a 12-month high of $38.75.

In other Dermira news, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total value of $499,288.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $27.34, for a total value of $82,020.00. The disclosure for this sale can be found here. In the last three months, insiders sold 36,258 shares of company stock valued at $985,873. 13.30% of the stock is owned by insiders.

Large investors have recently modified their holdings of the business. Platinum Investment Management Ltd. raised its position in Dermira by 28.8% in the 2nd quarter. Platinum Investment Management Ltd. now owns 57,700 shares of the biopharmaceutical company’s stock worth $1,681,000 after buying an additional 12,900 shares during the last quarter. Jennison Associates LLC raised its position in Dermira by 0.3% in the 3rd quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock worth $71,300,000 after buying an additional 7,746 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in Dermira by 24.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 140,495 shares of the biopharmaceutical company’s stock worth $4,095,000 after buying an additional 27,259 shares during the last quarter. Vanguard Group Inc. raised its position in Dermira by 9.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock worth $40,735,000 after buying an additional 125,157 shares during the last quarter. Finally, Rhumbline Advisers raised its position in Dermira by 57.1% in the 2nd quarter. Rhumbline Advisers now owns 43,781 shares of the biopharmaceutical company’s stock worth $1,276,000 after buying an additional 15,905 shares during the last quarter. 99.47% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This report was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/01/13/dermira-derm-lifted-to-hold-at-zacks-investment-research.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Get a free copy of the Zacks research report on Dermira (DERM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.